Eisai launches subsidiary operations to boost business activities in Israel

Japan headquartered firm Eisai has launched its pharmaceutical sales subsidiary, a fully-fledged operations and business activities in Tel Aviv in the State of Israel.

Israel’s pharmaceutical market reached $5.3 billion in 2021. The compound annual growth rate of the Israel pharmaceutical market from 2018 to 2021 was +8.56% and the market is expected to continue to grow steadily, with a high penetration rate of innovative medicines.

In 2011, Eisai Europe started business in Israel marketing and selling Eisai products through local distribution partners, and mainly marketed Lenvima, Halaven, Fycompa and Inovelon.

Eisai Israel was established in August 2021, and in January 2023, became the marketing authorisation holder of the Eisai products in Israel. Eisai Israel will now perform sales and marketing activities for these products. The company plans to launch its other global brands in the future.

With the commencement of operations at Eisai Israel, Eisai aims to utilize its own drug sales system in Israel, deliver innovative new drugs to more patients in Israel.